Skip to main content

Symposium on Hidradenitis Suppurativa Advances (SHSA), 2026

Filter
Filter
⁨⁨⁨⁨Keyword (eg, author, condition)
Content type:
Clear filters
Bimekizumab in Hidradenitis Suppurativa: Real-World Satisfaction Results from Hi-BEAT in the US
Hadar Lev-Tov, Ana Filipa Macedo, Frederik Fierens, et al.
Bimekizumab Improves Patient-Reported Outcomes Regardless of Baseline DT Count: 3-Year BE HEARD Trial
Christopher J. Sayed, Martina L. Porter, Jamie Weisman, et al.
Bimekizumab in Black/African American Hidradenitis Suppurativa Patients: 3-Year BE HEARD EXT Data
Tiffany Mayo, Raj Chovatiya, Vivian Y. Shi, et al.
Bimekizumab in Black/African American Patients with Hidradenitis Suppurativa: 3-Year BE HEARD EXT Data
Tiffany Mayo, Raj Chovatiya, Vivian Y. Shi, et al.
Bimekizumab vs Emerging and Existing Therapies in Moderate to Severe HS: a Network Meta-Analysis
Haley B. Naik, Amit Garg, April Armstrong, et al.
Bimekizumab Improves HRQoL in Patients with Moderate to Severe HS: 3-Year BE HEARD EXT HiSQOL Data
Vivian Y. Shi, John R. Ingram, Linnea Thorlacius, et al.
Bridging Perspectives in HS: Key Learnings from HCP, Patient, and Caregiver Input at the HS Summit
Beau DiCicco, Douglas DiRuggiero, Leigh Ann Pansch, et al.
HS PROGRESS Registry: Real-World Patient Characteristics and Unmet Needs
Haley B. Naik, Afsaneh Alavi, Joerg Albrecht, et al.
Bimekizumab Efficacy and Safety Over 4 Years in Patients with Moderate to Severe HS: Results from the BE HEARD EXT OLE2 in 4 Countries
Falk G. Bechara, Christopher J. Sayed, Amit Garg, et al.
Bimekizumab Efficacy and Safety Over 4 Years in Patients with Moderate to Severe HS: Results from the BE HEARD EXT OLE2 in 4 Countries
Falk G. Bechara, Christopher J. Sayed, Amit Garg, et al.